Ignite Creation Date:
2025-12-24 @ 6:58 PM
Ignite Modification Date:
2026-01-10 @ 3:19 PM
Study NCT ID:
NCT04523857
Status:
RECRUITING
Last Update Posted:
2025-04-04
First Post:
2020-08-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
UPCC 10119
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None